Archives of Gynecology and Obstetrics

, Volume 287, Issue 2, pp 251–260

Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach

General Gynecology



Heavy menstrual bleeding (HMB) is an important health problem affecting up to 30 % of reproductive age women, interfering with their quality of life. Medical therapy, with the avoidance of unnecessary surgery, is an attractive option.


To provide a comprehensive review of the current medical treatments available for idiopathic HMB and to focus on the newly introduced modalities. Furthermore, to provide a practical algorithm based on the best available evidence.


A PubMed search was conducted looking for the different trials, reviews and various guidelines relating to medical treatment of idiopathic HMB.


The most effective medical treatment for idiopathic HMB is the levonorgestrel-releasing intrauterine system. It provides a reliable long-term effect. Importantly, there is a growing scientific evidence for new modalities entailing; modified-release formulation of tranexamic acid, the new four-phasic estradiol valerate/dienogest contraceptive pills and combined contraceptive vaginal ring. Also, vaginal danazol has been tried.


Maintenance of status quo, i.e., keeping first-line treatment of idiopathic HMB as medical treatment is an essential issue. Modified-release formulation of tranexamic acid, the new four-phasic contraceptive pills and contraceptive vaginal ring are recently added to the medical armamentarium for treatment of idiopathic HMB increasing its efficacy.


Medical treatment Idiopathic Heavy menstrual bleeding Menorrhagia 


  1. 1.
    Hallberg L, Högdahl AM, Nilsson L, Rybo G (1966) Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 45:320–351. doi:10.3109/00016346609158455 PubMedCrossRefGoogle Scholar
  2. 2.
    Fraser IS, Critchley HO, Broder M, Munro MG (2011) The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 29:383–390. doi:10.1055/s-0031-1287662 PubMedCrossRefGoogle Scholar
  3. 3.
    Munro MG, Critchley HO, Fraser IS (2012) The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them? Am J Obstet Gynecol. doi:10.1016/j.ajog.2012.01.046 Google Scholar
  4. 4.
    Fraser IS, Critchley HO, Munro MG, Broder M (2007) Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 22:635–643. doi:10.1093/humrep/del478 PubMedCrossRefGoogle Scholar
  5. 5.
    Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229. doi:10.1016/j.ajog.2003.11.016 PubMedCrossRefGoogle Scholar
  6. 6.
    Shapley M, Jordan K, Croft PR (2004) An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 54:359–363PubMedGoogle Scholar
  7. 7.
    Harlow SD, Campbell OM (2004) Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG 111:6–16. doi:10.1046/j.1471-0528.2003.00012.x PubMedCrossRefGoogle Scholar
  8. 8.
    Santos IS, Minten GC, Valle NC et al (2011) Menstrual bleeding patterns: a community-based cross-sectional study among women aged 18–45 years in Southern Brazil. BMC Womens Health 11:26. doi:10.1186/1472-6874-11-26 PubMedCrossRefGoogle Scholar
  9. 9.
    Matteson KA, Boardman LA, Munro MG, Clark MA (2009) Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil Steril 92:205–216. doi:10.1016/j.fertnstert.2008.04.023 PubMedCrossRefGoogle Scholar
  10. 10.
    Shapley M, Jordan K, Croft PR (2002) Why women consult with increased vaginal bleeding: a case control study. Br J Gen Pract 52:108–113PubMedGoogle Scholar
  11. 11.
    Shankar M, Chi C, Kadir RA (2008) Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 14:15–20. doi:10.1111/j.1365-2516.2007.01586.x PubMedGoogle Scholar
  12. 12.
    National Collaborating Centre for Women’s and Children’s Health/National Institute for Health and Clinical Excellence (2007) Heavy menstrual bleeding. NICE clinical guideline 44, RCOG Press, London, UK. Available at:
  13. 13.
    Duckitt K, Collins S (2012) Menorrhagia. Clin Evid (Online). 18 Jan 2012. pii: 0805Google Scholar
  14. 14.
    Critchley HO, Maybin JA (2011) Molecular and cellular causes of abnormal uterine bleeding of endometrial origin. Semin Reprod Med 29:400–409. doi:10.1055/s-0031-1287664 PubMedCrossRefGoogle Scholar
  15. 15.
    Nelson AL, Teal SB (2007) Medical therapies for chronic menorrhagia. Obstet Gynecol Surv 62:272–281. doi:10.1097/01.ogx.0000259228.70277.6f PubMedCrossRefGoogle Scholar
  16. 16.
    Drife JO (2011) Oral contraceptives and heavy periods (editorial). Obstet Gynecol 117:773–774. doi:10.1097/AOG.0b013e318212b333 PubMedCrossRefGoogle Scholar
  17. 17.
    Clarke J (2010) Treatment of heavy menstrual bleeding (editorial). BMJ 341:c3771. doi:10.1136/bmj.c3771 PubMedCrossRefGoogle Scholar
  18. 18.
    Lukes AS, Kouides PA, Moore KA (2011) Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:151–158. doi:10.2217/whe.11.9 CrossRefGoogle Scholar
  19. 19.
    Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS (2011) Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 117:777–787. doi:10.1097/AOG.0b013e3182118ac3 PubMedCrossRefGoogle Scholar
  20. 20.
    Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E (2004) Why consider vaginal drug administration? Fertil Steril 82:1–12. doi:10.1016/j.fertnstert.2004.01.025 PubMedCrossRefGoogle Scholar
  21. 21.
    Abu Hashim H, Alsherbini W, Bazeed M (2012) Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252. doi:10.1016/j.contraception.2011.07.012 Google Scholar
  22. 22.
    Luisi S, Razzi S, Lazzeri L, Bocchi C, Severi FM, Petraglia F (2009) Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril 92:1351–1354. doi:10.1016/j.fertnstert.2008.08.017 PubMedCrossRefGoogle Scholar
  23. 23.
    Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC (2006) Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 252:191–200. doi:10.1016/j.mce.2006.03.025 PubMedCrossRefGoogle Scholar
  24. 24.
    Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E (2012) The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 285:117–121. doi:10.1007/s00404-011-1902-1 PubMedCrossRefGoogle Scholar
  25. 25.
    Kaunitz AM, Inki P (2012) The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs 72:193–215. doi:10.2165/11598960-000000000-00000 PubMedCrossRefGoogle Scholar
  26. 26.
    Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L (2009) Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 113:1104–1116. doi:10.1097/AOG.0b013e3181a1d3ce PubMedGoogle Scholar
  27. 27.
    Bahamondes MV, de Lima Y, Teich V, Bahamondes L, Monteiro I (2012) Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. Contraception. doi:10.1016/j.contraception.2011.12.005 Google Scholar
  28. 28.
    Matteson KA, Anderson BL, Pinto SB, Lopes V, Schulkin J, Clark MA (2011) Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists. Am J Obstet Gynecol 205:321.e1–8. doi:10.1016/j.ajog.2011.05.016
  29. 29.
    Farquhar C, Brown J (2009) Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000154. doi:10.1002/14651858.CD000154
  30. 30.
    Fraser IS, McCarron G (1991) Randomized trial of 2 hormonal and 2 prostaglandin- inhibiting agents in women with a complaint of menorrhagia. Aust N Z J of Obstet Gynaecol 31:66–70. doi:10.1111/j.1479-828X.1991.tb02769.x CrossRefGoogle Scholar
  31. 31.
    Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M (2009) A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 31:340–347PubMedGoogle Scholar
  32. 32.
    Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH (2011) Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 83:48–54. doi:10.1016/j.contraception.2010.06.011 PubMedCrossRefGoogle Scholar
  33. 33.
    Miller L, Notter KM (2001) Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98:771–778PubMedCrossRefGoogle Scholar
  34. 34.
    Collaborative Study Group on the Desogestrel containing Progestogen-only Pill (1998) A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3:169–178CrossRefGoogle Scholar
  35. 35.
    Lethaby A, Irvine G, Cameron I (2008) Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev (1):CD001016. doi:10.1002/14651858.CD001016.pub2
  36. 36.
    Fraser IS (1990) Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 30:353–356. doi:10.1111/j.1479-828X.1990.tb02028.x PubMedCrossRefGoogle Scholar
  37. 37.
    Kriplani A, Kulshrestha V, Agarwal N, Diwakar S (2006) Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 26:673–678. doi:10.1080/01443610600913932 PubMedCrossRefGoogle Scholar
  38. 38.
    Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT (1998) Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 105:592–598. doi:10.1111/j.1471-0528.1998.tb10172.x PubMedCrossRefGoogle Scholar
  39. 39.
    Lethaby A, Farquhar C, Cooke I (2000) Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev (4):CD000249. doi:10.1002/14651858.CD000249
  40. 40.
    Lumsden MA, Wedisinghe L (2011) Tranexamic acid therapy for heavy menstrual bleeding. Expert Opin Pharmacother 12:2089–2095. doi:10(1517/14656566),2011,598857 PubMedCrossRefGoogle Scholar
  41. 41.
    Naoulou B, Tsai MC (2012) Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand. doi:10.1111/j.1600-0412.2012.01361.x PubMedGoogle Scholar
  42. 42.
    Moore K, Morin I, Marenco T et al (2012) Pharmacokinetic studies of two novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. Am J Ther 19:190–198. doi:10.1097/MJT.0b013e318205427a PubMedCrossRefGoogle Scholar
  43. 43.
    Lukes A, Moore KA, Muse KN et al (2010) Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:865–875. doi:10.1097/AOG.0b013e3181f20177 PubMedCrossRefGoogle Scholar
  44. 44.
    Freeman EW, Lukes A, VaDrie D, Mabey RG, Gersten J, Adomako TL (2011) A dose–response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol 205:319.e1–7. doi:10.1016/j.ajog.2011.05.015
  45. 45.
    Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D (2009) Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80:436–444. doi:10.1016/j.contraception.2009.03.018 PubMedCrossRefGoogle Scholar
  46. 46.
    Jensen JT (2010) Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 11:1147–1157. doi:10.1517/14656561003724713 PubMedCrossRefGoogle Scholar
  47. 47.
    Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J (2010) Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 149:57–62. doi:10.1016/j.ejogrb.2009.11.001 PubMedCrossRefGoogle Scholar
  48. 48.
    Whalen KL, Rose R (2011) Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother 45:1256–1261. doi:10.1345/aph.1Q216 PubMedCrossRefGoogle Scholar
  49. 49.
    Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W (2011) Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 11:159–170. doi:10.2165/11591200-000000000-00000 PubMedCrossRefGoogle Scholar
  50. 50.
    Borgelt LM, Martell CW (2012) Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther 34:37–55. doi:10.1016/j.clinthera.2011.11.006 PubMedCrossRefGoogle Scholar
  51. 51.
    Fraser IS, Römer T, Parke S et al (2011) Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing oestradiol valerate and dienogest: a randomised, double-blind phase III trial. Hum Reprod 26:2698–2708. doi:10.1093/humrep/der224 PubMedCrossRefGoogle Scholar
  52. 52.
    Micks E, Jensen JT (2011) Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 7:513–524. doi:10.2217/WHE.11.49 CrossRefGoogle Scholar
  53. 53.
    Kiley JW, Shulman LP (2011) Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health 3:281–286. doi:10.2147/IJWH.S22645 PubMedCrossRefGoogle Scholar
  54. 54.
    Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J (2011) Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomized, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 16:258–269. doi:10.3109/13625187.2011.591456 PubMedCrossRefGoogle Scholar
  55. 55.
    Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M (2012) Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception 86:96–101. doi:10.1016/j.contraception.2011.11.011 PubMedCrossRefGoogle Scholar
  56. 56.
    Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT (2010) Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 116:625–632. doi:10.1097/AOG.0b013e3181ec622b PubMedCrossRefGoogle Scholar
  57. 57.
    Reid PC, Virtanen-Kari S (2005) Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 112:1121–1125. doi:10.1111/j.1471-0528.2005.00642.x PubMedCrossRefGoogle Scholar
  58. 58.
    Roumen FJ (2007) The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 75:420–429. doi:10.1016/j.contraception.2007.01.013 PubMedCrossRefGoogle Scholar
  59. 59.
    Mulders TM, Dieben TO (2001) Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 75:865–870. doi:10.1016/S0015-0282(01)01689-2 Google Scholar
  60. 60.
    Oddsson K, Leifels-Fischer B, Wiel-Masson D et al (2005) Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 20:557–562. doi:10.1093/humrep/deh604 PubMedCrossRefGoogle Scholar
  61. 61.
    Sabatini R, Cagiano R (2006) Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 74:220–223. 10.1016/j.contraception.2006.03.022 PubMedCrossRefGoogle Scholar
  62. 62.
    Janssen CA, Scholten PC, Heintz AP (1995) A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 85:977–982PubMedCrossRefGoogle Scholar
  63. 63.
    Zakherah MS, Sayed GH, El-Nashar SA, Shaaban MM (2011) Pictorial blood loss assessment chart in the evaluation of heavy menstrual bleeding: diagnostic accuracy compared to alkaline hematin. Gynecol Obstet Invest 71:281–284. doi:10.1159/000320336 PubMedCrossRefGoogle Scholar
  64. 64.
    Lopez LM, Grimes DA, Gallo MF, Schulz KF (2010) Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev (3):CD003552. doi:10.1002/14651858.CD003552.pub3
  65. 65.
    Bahamondes V, Bahamondes L (2012) “This interesting study shows that that both the contraceptive vaginal ring (CVR) and norethisterone (NET…” Evaluation of: [Abu Hashim H et al. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 85:246–252; doi:10.1016/j.contraception.2011.07.012]. Faculty of 1000, 07 Dec 2011. Scholar
  66. 66.
    Beaumont H, Augood C, Duckitt K, Lethaby A (2007) Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev (3):CD001017. doi:10.1002/14651858.CD001017.pub2

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Mansoura Faculty of MedicineMansoura UniversityMansouraEgypt

Personalised recommendations